chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I tested positive for Covid-19 on March 23, 2023 my symptoms were sore throat, cough, fever of 101.00, tiredness. I was taking DAYQUIL, and TYLENOL for my symptoms.
Lack of response - Information has been received from a pharmacist concerning a male who in 1990 and 1991 was vaccinated with the first and second dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine  live (second generation).  Concomitant therapy included finasteride (MSD).  In 2000 the patient had no detectable antibodies.  Additional information has been requested.
Narrative:  First Shingrix vaccine given and shortly after, patient became hypotensive. Patient was given epinephrine, and transported to Hospital
I82.401 ACUTE DVT OF RIGHT LEG, UNSPECIFIED VEIN 3/7/2022 DEHYDRATION
12 year old received her first dose of the Moderna; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (12 year old received her first dose of the Moderna) in a 12-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Aug-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (12 year old received her first dose of the Moderna). On 20-Aug-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (12 year old received her first dose of the Moderna) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant products was provided by the reporter. No treatment information was provided by the reporter.
In neck same side as arm injection site two lymph nodes became hot, painful, and then massively swollen.
upper back pain; neck pain; Thirsty; hungry; Nausea and feeling of vomit; Wrist /Hip/ joint pain; Swollen throat; Left under arm lymph node swollen, swollen lymph node behind ears near jaw and below chin; This is a spontaneous report from a non-contactable consumer, the patient. A 46-year-old non-pregnant female patient received a first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) as single dose via an unspecified route of administration on left arm on 11Mar2021 at 18:30 (at the age of 46-years-old) for COVID-19 immunisation. Medical history and concomitant medications were not reported. It was reported that none other medications received by the patient within 2 weeks of vaccination. The patient did not have any allergies to medications, food, or other products. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to and since vaccination, the patient was not been diagnosed with COVID-19. On 11Mar2021 at 20:30, the patient experienced hungry, nausea and feeling of vomit, neck pain, swollen throat, thirsty, upper back pain, wrist /hip/ joint pain and also reported left under arm lymph node swollen, swollen lymph node behind ears near jaw and below chin. The patient says no fever and it was a week after 1st dose and symptoms still existed and she felt like she was overdosed. The patient visited Doctor or other healthcare professional office/clinic and she reported the same to physician and waiting for response. Therapeutic measures taken was unknown. The clinical outcome of events hungry, nausea and feeling of vomit, neck pain, swollen throat, thirsty, upper back pain, wrist /hip/ joint pain, left under arm lymph node swollen, swollen lymph node behind ears near jaw and below chin were not recovered. No follow-up attempts are needed. No further information is expected.
Client received Pfizer dose @ 1543 . Approximately 15 minutes later @ 1602 client began to experience itchy throat, numb hands and arms, left sided swelling in throat while swallowing.  No wheezing upon auscultation of lungs. BP 110/60, HR 130, O2 sat 98% . Slow deep breathing and calming measures  implemented with client. 25 mg benadryl PO given.  Advised husband to drive.  Client observed for 30 minutes without worsening symptoms.  Client left @1639 and was on educated on if symptoms don't improve or worsen, to call 911.
Really tired; Arm hurt; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Really tired) and VACCINATION SITE PAIN (Arm hurt) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (Really tired) and VACCINATION SITE PAIN (Arm hurt). At the time of the report, FATIGUE (Really tired) and VACCINATION SITE PAIN (Arm hurt) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       No concomitant medications was included. No treatment drug details was provided.
Information has been received from a physician via medical records concerning a 14 day old with a history of circumcision premature (reported in WAES0707USA01443) male who on 30-Aug-2007 was vaccinated with RECOMBIVAX (Lot # 655565/0007U) in the left vast lateralis. On 13-Sep-2007 the baby was taken to the physician with concerns of diaper area being very raw looking. Genitourinary examination showed erythematous. The baby was diagnosed with candial dermatitis and was treated with nystatin cream, four times a day for 14 days. On Sep-2007, the baby was seen by the doctor again. No abnormality was found. The baby recovered from candial dermatitis. On 07-Nov-2007 the baby was seen by the doctor with concerns of diarrhea for 3 to 4 days. Physical examination did not show any abnormality. There was no documented treatment. The patient subsequently developed adverse events after vaccination with OMPC (WAES # 0908USA00771) and adverse events after vaccination with RECOMBIVAX (WAES # 0908USA00772). Additional information is not expected.
An RN reported that, post vax, the 50 year-old Caucasian female with lymphoma and a history of cancer (type unspecified), chemotheraoy which ended in mid-September 2000. Upper extremity edema after receiving a tetanus injection and steroid therapy (prednisone) which stopped the last week of September 2000, who on 11/16/2000 was vaccinated with pneumococcal vaccine 23 polyvalent. (Lot 3 6945K invalid) intramuscularly in the left deltoid. Concomitant vaccination on 11/16/2000 included influenza virus vaccine (E64710HA) intramuscularly in the right deltoid. The pt experienced intermittent symptoms of achy left arm and pain that radiated down the left arm. The pt told the RN that once "the arm ached so bad that it made her sick to her stomach". She also reported that the outer aspect of the elbow was sore to the touch but the pt stated that "the elbow is better now". The pt told the RN that she had a lump under her left arm "that comes and goes". The RN reported that the pt thinks the lump under her arm "had to do with her lymph system". Unspecified medical attention was sought. In follow-up, the RN reported that on 11/16/00, shortly after receiving pneumococcal vaccine 23 polyvalent, the pt's left arm became sore and radiated downward toward the hand. She reported that a month later, the outer aspect of the elbow was sore to the touch, "which comes and goes". She reported that the pt had enlarged lymph nodes which ached to the point of causing nausea, which she states "occurs on and off". She stated that the pt's arm swelled when touched. The RN reported that the outcome of the pt's experiences were unknown. The sore arm, elbow sore to touch, enlarged lymph nodes, nausea and arm swelling were determined to be an "Other Important Medical Event. F/U In follow up the registered nurse reported that the pt was seen by her private family physician and the pt was treated with antibiotics. The symptoms persisted. The pt was sent back to her oconlogist. Lymphoma had reoccurred. The pt has since undergone a bone marrow transplant. The worsening lymphoma required hospitalization and was considered life threatening. The sore arm, elbow sore to touch, enlarged lymph nodes, nausea and arm swelling were determined to be an other important medical event.  In FOLLOW-UP, the registered nurse reported that the patient had returned to teaching and was doing well as the time of the current report. She reported that the patient had a bone marrow implant in the summer of 2001 and had recovered from her experience No further information is available.
8-23-2012 el622 Redness, raised, warm to touch. 2" length 1" width. To R arm where varicella inj was administered. Pt denies itching, N/V, stinging, burning to size. Pt stated she noticed spot around 12pm today when fixing hair. Pt was recommended to take Benadryl as directed for age.
Narrative: Pt. passed away on 3/25/22 at approximately 8:30pm under the care of Hospice.
Tinnitus- (high-pitch hissing) in both ears still persists. I have never  before experienced this.
Information has been received from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. In 2013 the patient was vaccinated with ZOSTAVAX, (lot# and route unknown) as recommended for routine adult health maintenance for the prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster also known as shingles and other complications. In 2015, the patient was treated at a medical facility for a blistering vesicular outbreak, that was diagnosed as herpes zoster, or shingles.  As a direct and proximate result of the zoster vaccine live (ZOSTAVAX) vaccine, and/or despite receiving zoster ZOSTAVAX, for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment.  As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Vaccinated 12/21 at 6:00 am. symptoms began roughly midnight. "horrible headache". notes that her left hurt badly and difficult to move.  Reports she has taken advil and Tylenol and notes that these have been effective.  reports still feeling fatigued, but isn't sure if that's related to lack of sleep from the headache or part of a reaction.  Arm is still sore, but is not really painful the way it was last night.  Still has a slight headache.
I started with a scratchy throat with a cough, not a very productive cough. I lost my taste and smell and I still don't have that back. I was really achy and fatigued. I still get tired easily . I went to Urgent Care for test it was positive and the next day on Sunday the 15th they scheduled me for an infusion. I started feeling better after the infusion.
Customer called and wanted FLUZONE HD lot # and expiration date because got hives from this. She has a history of chronic urticaria as well so it was hard to tell. Had to see MD due to this.
No adverse effects reported; Multiple patients were vaccinated with improperly stored ROTATEQ on multiple dates; Information has been received from a medical assistant concerning a patient of unknown age, gender and race. The patient's medical history, drug allergies, previously drug reactions, concurrent conditions and concomitant medications were not reported.  On 04-MAY-2019, the patient was vaccinated with an improperly stored dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) orally for prophylaxis (lot number reported as R021930 with expiration date in 18-JUN-2020) (strength and anatomical location were not provided).  The Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) was stored at an unknown temperature for an unknown time frame. There was a previous temperature excursion and the call was because of a data logger.  No adverse effects reported.  Lot number R021930 is an invalid lot number for Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ).  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1907USA001848: US-009507513-1907USA001849: US-009507513-1906USA011434: US-009507513-1907USA001793: US-009507513-1907USA001794: US-009507513-1907USA001795: US-009507513-1907USA001796: US-009507513-1907USA001797: US-009507513-1907USA001798: US-009507513-1907USA001799: US-009507513-1907USA001800: US-009507513-1907USA001801: US-009507513-1907USA001802: US-009507513-1907USA001803: US-009507513-1907USA001804: US-009507513-1907USA001805: US-009507513-1907USA001806: US-009507513-1907USA001807: US-009507513-1907USA001808: US-009507513-1907USA001809: US-009507513-1907USA001810: US-009507513-1907USA001811: US-009507513-1907USA001812: US-009507513-1907USA001813: US-009507513-1907USA001814: US-009507513-1907USA001815: US-009507513-1907USA001816: US-009507513-1907USA001817: US-009507513-1907USA001818: US-009507513-1907USA001819: US-009507513-1907USA001820: US-009507513-1907USA001821: US-009507513-1907USA001822: US-009507513-1907USA001823: US-009507513-1907USA001824: US-009507513-1907USA001825: US-009507513-1907USA001826: US-009507513-1907USA001827: US-009507513-1907USA001828: US-009507513-1907USA001829: US-009507513-1907USA001830: US-009507513-1907USA001831: US-009507513-1907USA001832: US-009507513-1907USA001833: US-009507513-1907USA001836: US-009507513-1907USA001835: US-009507513-1907USA001837: US-009507513-1907USA001838: US-009507513-1907USA001839: US-009507513-1907USA001840: US-009507513-1907USA001841: US-009507513-1907USA001842: US-009507513-1907USA001843: US-009507513-1907USA001844: US-009507513-1907USA001845: US-009507513-1907USA001846: US-009507513-1907USA001847: US-009507513-1907USA000952: US-009507513-1907USA000989: US-009507513-1907USA000962: US-009507513-1907USA000988: US-009507513-1907USA000963: US-009507513-1907USA000953: US-009507513-1907USA000959: US-009507513-1907USA000968: US-009507513-1907USA000967: US-009507513-1907USA000964: US-009507513-1907USA000966: US-009507513-1907USA000954: US-009507513-1907USA000969: US-009507513-1907USA000970: US-009507513-1907USA000965:
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare providers recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 28-NOV-2012, a healthcare provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 08-DEC-2012, the patient was treated by a healthcare provider for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Patient experienced altered mental status, fever, imbalance and lower extremity weakness. Was hospitalized from 9/24-9/26. Discharged 9/26.
This spontaneous report was received from a medical assistant and refers to multiple unspecified patients of unknown demographics. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On unknown dates, the patients received doses of improperly stored LIQUID PEDVAXHIB (lot # K004540, expiration date: 03-DEC-2016; lot # L014429, expiration date: 15-MAR-2018; dose and route were not provided). The vaccine underwent temperature excursion of 1 degree Celsius for 158 total cumulative hours, which was detected by a data logger. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
The patient experienced raised areas bilaterally. The patient complained of pain in her neck and lymphadenopathy.
administered to patient(s) after experiencing a temperature excursion; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (administered to patient(s) after experiencing a temperature excursion) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048C21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (administered to patient(s) after experiencing a temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (administered to patient(s) after experiencing a temperature excursion) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   No treatment information was provided. Reporter asked for accurate expiration date and time for unpunctured (thawed) moderna vaccine which was out of temperature (~ 66 degrees) at 10:30 pm on 12-JUL-2021, as vaccine was back in good temperature at 10:32 am on 13-JUL-2021, and also asked whether new expiration date is on 13-OCT-2021 t 10:30 pm ?
After giving the last injection which was HPV patient stated she didn't feel well and then her eyes fluttered then she passed out. Patients mom was standing next to her and caught her we laid her down and she woke up instantly. I gave patient some water when she felt better she sat back up I took her BP which was very low I let PA know what was going on and she advised I let the patient sit an extra 15 minutes on top of the 15 she was already doing and check BP again. I continued to check on patient and she felt fine although BP was still low patient was feeling fine and was released to go home told to rest and drink a lot of fluids.
Arm of the injection turned pink (medium rare) 2nd dose; Arm warm to touch; intense itching; whole arm down to elbow got swollen after 2nd dose; This spontaneous case report was received from a 75 year old female patient who received first dose of Moderna COVID-19 Vaccine (mRNA-1273) on 21-Jan-2021 and experienced swelling and redness on the arm of the injection that lasted 3 or 4 days. She took second dose of the vaccine on 18-Feb-2021 and experienced the arm of the injection turned pink ("medium rare") and her whole arm, down to the elbow, got swollen. Also, it was warm to the touch.  The concomitant medications of the patient included quinapril,omeprazole and levothyroxine. The patient's past medical history was not provided.  On 21-Jan-2021, the patient took first dose of Moderna COVID-19 Vaccine for COVID-19 vaccination intramuscularly into the arm. She experienced swelling and redness on the arm of the injection that lasted 3 or 4 days. The patient got her second dose on 18-Feb-2021 intramuscularly into another arm, and the arm of the injection turned pink ("medium rare") and her whole arm down to the elbow, got swollen. Also, it was warm to the touch. Now, the swelling was going down but there was an intense itching that still persisted.  Topical Benadryl and Ice cubes were used for treatment.  Action taken with mRNA-1273 in response to the event was unknown.  The outcome for events of swelling after second dose was reported as recovering and outcome for the event event of itching was reported as not recovered. The outcome for events of erythema and vaccination site warmth was unknown.  The reporter causality for the events was not provided.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments:  MOD-2021-023613:Same patient, 1st dose
Headache, Myalgia, Fever, NauseaVomiting, chills, shaking Narrative:  Headache, Myalgia, Fever tmax 102.8, nausea, chills, shaking; 48 hours-resolving, "functioning with Tylenol and ibuprofen"
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. In approximately 2014 (reported as: or about 2014), the patient was inoculated with ZOSTAVAX (strength, route, anatomical location, dose, frequency, dose number, lot number and expiration date were not reported), for the permanent prevention and protection against shingles and zoster-related conditions/injuries. On an unknown date, the patient was diagnosed with shingles (herpes zoster) and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result. In addition, the patient would continue to suffer ongoing injuries, included but not limited to: mental and physical pain and suffering, extensive medical care and treatment for these injuries, significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of pre-existing conditions and activations of latent conditions, lost wages, loss of earning capacity and other losses and damages. On or about 2016, the patient was treated for shingles. At the time of the report, the outcome of the aforementioned adverse events was unknown, excepting for the events of emotional distress and pain that was reported as not resolved. The relatedness assessment between the aforementioned adverse events and ZOSTAVAX was related. The reporter considered the events as serious for the following reasons: Hospitalization, life-threatening, disability and medical significant.
Developed chills, fever (102), headache, body aches, back pain, sore arm at injection site. I had covid March 2020.